Evoke Pharma Dividend

Dividend criteria checks 0/6

Evoke Pharma does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.92
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Evoke Pharma announces positive findings from second GIMOTI market research study

Jun 15

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Jun 08

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Jun 02

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Mar 14

Evoke Pharma shares surge on positive findings from Gimoti market research study

Jan 13

Evoke Pharma EPS beats by $0.02

Nov 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if EVOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EVOK's dividend payments have been increasing.

Dividend Yield vs Market

Evoke Pharma Dividend Yield vs Market

How does EVOK dividend yield compare to the market?
Segment	Dividend Yield
Company (EVOK)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (EVOK)	n/a

Notable Dividend: Unable to evaluate EVOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EVOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate EVOK's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EVOK has not reported any payouts.

Evoke Pharma Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Consensus EPS estimates fall by 13%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 57%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma (NASDAQ:EVOK) Is Using Debt Safely

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Price target decreased to US$7.00

Consensus revenue estimates increase by 25%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Evoke to get US patent for nasal spray Gimoti

Consensus revenue estimates fall by 19%

Price target decreased to US$63.50

Evoke Pharma Q2 GAAP loss per share narrows, revenue up

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma gets Canadian patent linked to Gimoti nasal spray

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Price target decreased to US$6.50

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

Consensus EPS estimates fall by 29%

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$9.50

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Price target increased to US$9.50

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$1.28m

Does Evoke Pharma (NASDAQ:EVOK) Have A Healthy Balance Sheet?

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma announces positive findings from second GIMOTI market research study

Evoke Pharma pops 8% after Gimoti listed in FDA Orange Book

Evoke Pharma issued new U.S. patent covering methods of use for Gimoti

Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis

Independent Director has left the company

Consensus revenue estimates fall to US$1.04m

No longer forecast to breakeven

Consensus revenue estimates fall to US$2.84m

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit

Revenue and earnings miss expectations

New 90-day low: US$2.45

Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: US$2.52

Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.